Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 30, 2026, 7:00 AM ET
Fractyl Health announced it received a U.S. patent covering aspects of its Revita single-use catheter, with terms extending to November 28, 2042, and a Notice of Allowance for a thermal dosing method application.
Nasdaq: $GUTSRevita pivotal studyPlanned De Novo filingFunding and dilution
GUTS Stock Hub: Fractyl Health News, Revita and the FDA Path
Revita met the six-month pivotal co-primary endpoint. The one-year endpoint, planned FDA submission and funding remain separate tests. The October share combination supplies no operating cash. The October 29 regular-session close was $0.9915 (+11.40% versus October 28).
Full research report · PDF
Fractyl Health ($GUTS), research as of October 30, 2026
15 pages covering the existing long-form research, with the business, operating milestones, financial resources, dilution, ownership, risks, scenarios, sources and FAQ. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-guided regulatory window
Late Q4 2026 · planned De Novo submission
Fractyl plans a Revita marketing submission for post-GLP-1 weight maintenance. A planned submission is not FDA authorization. Filed business update
Twelve-month REMAIN-1 pivotal topline, including the second co-primary endpoint, is expected in Q1 2027. Potential late-2027 authorization and early-2028 launch are company scenarios, conditional on the necessary evidence and decisions.
GUTS stock at a glance
Close · October 29, 2026
$0.9915
Regular-session close; +11.40% versus $0.89 on October 28.
Cash and equivalents · June 30
$47.140M
Restricted cash of $4.255M is separate.
H1 operating cash use
$38.378M
Historical six-month consumption, not a forecast.
Restricted cash · June 30
$4.255M
Separate from cash and equivalents.
Share combination
1 for 12
Effective October 2; adjusted trading scheduled October 5.
Planned workforce reduction
~45%
October 22 business update; completion expected Q4 2026.
Runway outlook
Into Q2 2027
Company estimate after planned spending reductions, not an updated cash balance.
Quarterly burn objective
~$8M
Company operating cash-burn target by end of Q2 2027; not achieved June burn.
Where Fractyl Health stands now
June cash and equivalents were $47.140M, with $4.255M restricted cash separate; H1 operating cash use was $38.378M. The October 22 plan focuses on Revita, discontinues internal Rejuva development and projects runway into Q2 2027 following spending reductions. That outlook is conditional. Filed business update
Clinical durability and funding must support the planned regulatory path.
The six-month pilot analysis had p=0.07 one-sided; favorable subgroups were small. FDA feedback is non-binding, the one-year endpoint remains outstanding and June resources carried a going-concern uncertainty. The split creates no new cash.
The constructive case
The pivotal cohort met its six-month co-primary endpoint in the mITT population of 308 (p=0.0023), with no device- or procedure-related serious adverse events reported. A favorable one-year responder result, acceptable longer-term safety and adequate funding would strengthen the path toward the planned application.
The cautious case
The six-month pilot analysis had p=0.07 one-sided; favorable subgroups were small. FDA feedback is non-binding, the one-year endpoint remains outstanding and June resources carried a going-concern uncertainty. The split creates no new cash.
Latest Fractyl Health news
Oct 30, 2026
Revita patent portfolio update
The company identifies a catheter patent with a stated term to November 28, 2042 and an allowed thermal-dosing application. Patent protection and a planned FDA submission do not establish marketing authorization.
Oct 29, 2026
Company-sponsored survey: 33% of nearly 300 GLP-1 users preferred stopping the drug and receiving a hypothetical procedure
In company-sponsored research, 33% of nearly 300 current or recent GLP-1 users preferred stopping medication and receiving a hypothetical procedure. Stated preferences do not establish Revita efficacy, actual demand or regulatory authorization.
Oct 22, 2026
Revita focus: about 45% workforce cut, Rejuva development stopped, runway into Q2 2027
After the six-month REMAIN-1 pivotal result, Fractyl is concentrating its resources on Revita in post-GLP-1 weight maintenance. It will cut about 45% of its workforce, with the reduction expected to be completed in the fourth quarter of 2026 and estimated severance and related charges of about $2 million, mostly in that quarter. Internal development of the Rejuva gene therapy program is discontinued and the company is seeking strategic alternatives for it. With these measures it expects existing cash to fund operations into the second quarter of 2027 and quarterly operating cash burn to fall by about 50%, to about $8 million, by the end of that quarter. The co-founder, President and Chief Product Officer retires from his executive roles on October 30 and will remain a senior advisor; the chief executive officer also becomes President. The company restated its calendar: De Novo submission in late Q4 2026, 12-month REMAIN-1 topline in Q1 2027, potential FDA authorization in late 2027 and potential U.S. launch in early 2028. These are company plans, not regulatory decisions.
Oct 16, 2026
REMAIN-1 pivotal cohort meets its six-month co-primary endpoint
Fractyl Health reported that Revita met the first co-primary endpoint of the ongoing REMAIN-1 Pivotal Cohort, a 308-participant randomized, double-blind, sham-controlled study in adults with obesity who had lost at least 15% of body weight on tirzepatide before stopping it. According to the company, Revita participants maintained approximately 80% of their GLP-1-induced weight loss at six months versus 67% with sham, with least-squares mean weight regain of 5.1% versus 8.2% of body weight (difference −3.06 points, 95% CI −5.02 to −1.10, p=0.0023) in the modified intention-to-treat population ( presentation, Exhibit 99.2 ). The company reported no device- or procedure-related serious adverse events and no deaths through the September 24, 2026 data cut-off, with related events mostly mild and 94% occurring within seven days of the procedure. The second co-primary endpoint, the share of Revita participants keeping at least 5% total body-weight loss versus pre-tirzepatide weight at one year against a performance goal above 50%, remains outstanding; the company guides one-year topline data to Q1 2027 and plans a De Novo submission to the FDA in late Q4 2026. Revita remains investigational in the United States.
Oct 1, 2026
Reverse split timetable disclosed
The company disclosed a one-for-twelve share combination effective October 2, with adjusted trading scheduled October 5. The split changes the per-share scale and does not fund operations.
Aug 10, 2026
Second-quarter accounts provide the historical liquidity base
June cash and equivalents were $47.140M and H1 operating cash use was $38.378M. Subsequent operating-plan guidance is separate from that historical balance.
GUTS stock catalysts and operating watchpoints
- Late Q4 2026 — Planned FDA De Novo submission for Revita. Company submission window
- Q1 2027 — Twelve-month pivotal data, including second co-primary endpoint. Company data window
- Late 2027 / early 2028 · potential — Possible FDA authorization / U.S. launch in the company plan; neither assured. Conditional future scenarios
The regulatory path and the two primary endpoints
Fractyl’s regulatory strategy evolved during 2026. In January, the company reported seeking FDA feedback on a possible De Novo route rather than a premarket approval application. In March, it reported favorable pre-submission feedback: based on data from more than 300 procedures, the safety profile appeared consistent with a Class II device classification. The same release states that final pathway determinations depend on review of the complete safety dataset and that pre-submission feedback is advisory and non-binding.
The distinction is consequential. A De Novo classification request is not a routine administrative filing following a positive trial. Fractyl must submit evidence and the FDA must evaluate it. The company can describe a planned pathway, but that description cannot guarantee the agency’s final classification, the adequacy of the submission or authorization of the proposed indication. Breakthrough Device designation likewise does not replace the need to demonstrate safety and effectiveness.
Cash, operating costs and historical sensitivities
The June 30, 2026 balance sheet reports $47.140 million of cash and cash equivalents. A separate $4.255 million restricted-cash balance is not included in that figure and is not freely available operating liquidity. Cash and equivalents had been $81.540 million at December 31, 2025. Neither date is an October cash balance.
Operating activities consumed $38.378 million during the first six months of 2026. There were no purchases of property and equipment in that cash-flow statement. Financing activities provided a net $3.978 million, principally $4.058 million received from warrant exercises and $0.170 million from the employee stock purchase plan, less $0.250 million of finance-lease principal payments. The cash-flow bridge reconciles the $34.400 million decline in cash, equivalents and restricted cash over the half.
Merlintrader Health Score · $GUTS
2.40out of 5
Assessed October 16, 2026. Weighted calculation: 1.5×30% + 3.5×30% + 1.5×20% + 3.0×10% + 3.0×10% = 2.40. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Financial balances retain their reporting dates and are not current cash.
- Milestone guidance is conditional; execution, collection and per-share outcomes remain separate tests.
GUTS Stock FAQ: Fractyl Health Questions Answered
When is the next Fractyl Health GUTS stock catalyst?
Fractyl’s October 22, 2026 plan targets a Revita FDA De Novo submission in late Q4 2026 and 12-month REMAIN-1 pivotal topline in Q1 2027, including the second co-primary endpoint. Potential authorization in late 2027 and a U.S. launch in early 2028 remain company scenarios dependent on evidence and regulatory review. Regulatory and pivotal milestones.
Is Fractyl Health’s Revita FDA approved?
No: as of November 2, 2026, Revita is investigational in the United States. Favorable pre-submission feedback and Breakthrough Device designation do not secure De Novo authorization. REMAIN-1 met its six-month pivotal co-primary endpoint with p=0.0023; the one-year co-primary endpoint remains pending. FDA’s pathway feedback is advisory and non-binding. Current regulatory plan. Pivotal endpoint and review conditions.
How much cash does Fractyl Health have, and how long will it last?
Fractyl held $47.140 million cash and equivalents at June 30, 2026, with $4.255 million restricted cash separate; H1 operating use was $38.378 million. On October 22, management extended its funding outlook into Q2 2027 following planned spending reductions. The June filing reported going-concern doubt. Later spending, financing, covenant conditions and execution of those reductions can change the operating horizon. June resources and cash use. Revised funding outlook.
Is Fractyl Health at risk of dilution after its reverse split?
Yes: Fractyl’s 1-for-12 reverse split, effective October 2, 2026, did not remove the dilution risk from outstanding warrants, employee awards and future financing. Adjusted trading began October 5. The split consolidates shares and proportionately adjusts related securities without providing operating cash or validating the clinical program. Reverse-split timetable. Financing and equity instruments.
When does Fractyl Health report earnings?
As of November 2, 2026, Fractyl Health had not announced its next financial-results date. Its latest reported quarter ended June 30, 2026. Its late-Q4 regulatory submission and Q1 2027 pivotal-data windows concern development milestones rather than scheduled financial results. Latest quarterly filing. Development schedule. Current investor announcements.
What does Fractyl Health do?
Fractyl Health develops metabolic treatments, now focused on Revita, an endoscopic procedure designed to remodel the duodenal lining and help maintain weight loss after GLP-1 drug discontinuation. Revita remains investigational in the United States. The company is discontinuing internal Rejuva gene-therapy development and seeking strategic alternatives for that program. Current company focus.
What did Fractyl Health’s six-month Revita Midpoint Cohort show?
Fractyl’s January 29, 2026 REMAIN-1 Midpoint Cohort disclosure reported one-sided p=0.07 in the prespecified six-month efficacy population of 40 participants. An exploratory subgroup of 20 participants with above-median GLP-1 run-in weight loss produced p=0.004, one-sided. The cohort was not designed to be sufficiently powered for efficacy analysis and is distinct from the subsequent pivotal cohort. The subgroup finding does not replace the prespecified result. Pilot analysis and limitations.
What does Fractyl Health’s 84% weight-loss result mean?
Fractyl’s July 15, 2026 REMAIN-1 Midpoint Cohort update estimated 84% retention of prior GLP-1-induced weight loss at one year, versus 46% with sham, in an optimized subgroup. This subgroup required complete duodenal ablation over 14 cm and GLP-1 run-in weight loss of at least 17.5%; it comprised ten Revita and eight sham participants. The percentage measures retention of earlier weight loss, not total body-weight loss, and represents a small selected subgroup. One-year pilot and subgroup denominators.
Primary sources
- SEC Q2 Form 10-Q: financial statements, debt, warrants and operating plan
- SEC October 1 Form 8-K: reverse-split timetable
- SEC September 11 Form 8-K: Nasdaq notice
- SEC January 29 Form 8-K: six-month pilot
- SEC March 24 exhibit: regulatory feedback and post-hoc analyses
- Company June 4 release: REVEAL-1 results and safety
- SEC July 15 Form 8-K: one-year randomized pilot
- Company August 10 update: current guidance
- SEC April proxy: dated ownership and methodology
- SEC Bradley Form 4: September 14 purchase
- ClinicalTrials.gov REMAIN-1
- ClinicalTrials.gov REVITALIZE-1
- October 30 patent update
- October 29 company-sponsored patient research
- October 22 revised operating plan
Disclaimer. This content is independent analysis for educational and informational purposes. It is not investment advice, a recommendation, an offer or a solicitation to trade securities. Clinical development, regulatory review, financing and listing risks can change the assessment. Illustrative calculations are not forecasts.
Merlintrader may hold positions in securities mentioned. Some links are affiliate or referral links, including Finviz links, and may generate a commission at no additional cost to readers. Consult the disclaimer and terms and privacy pages.
